

SPONSORSHIP AGREEMENT

This sponsorship agreement (the “**Agreement**”) is made effective as of 01. January 2024 (the “**Effective Date**”), between Swedish Orphan Biovitrum A/S, Sorgenfrivej 17, 2800 Lyngby. CVR nr. 19179079 (“**Sobi**”) and Denmark’s Bleeding Association, Blekinge Boulevard 2, 2630 Taastrup (“**Recipient**”). The above Parties may also be referred to jointly as the “**Parties**” and individually as “**Party**”.

WHEREAS, Sobi A/S is an affiliate of an international biopharmaceutical company dedicated to rare diseases;

WHEREAS, Recipient is Denmark’s Bleeding Association; and

WHEREAS, Sobi has agreed to sponsor Denmark’s Bleeding Association further development of the Telemedicine App solution. (the “**Event**”) on the terms and conditions set out below.

NOW, THEREFORE, the parties agree as follows:

1. TERMS AND CONDITIONS OF SPONSORSHIP

- 1.1 Sponsorship: Sobi hereby agrees to sponsor the Event by paying the total amount of 100.000 DKK + applicable VAT for the purpose as specified in Schedule 1. (the “Sponsorship”).
- 1.2 Scope: The Sponsorship shall only cover actual, documented, reasonable and direct costs that are necessary in order to carry out the Meeting, as further specified in Schedule 1. Recipient warrants that Sobi’s support under this Agreement shall be used solely for the Sponsorship in compliance with this Agreement, that the Sponsorship and Event will be carried out in accordance with all applicable laws, regulations and industry code requirements, including without limitation, any transparency regulations and disclosures (“Applicable Law”) and that any activities performed and materials generated in connection with the Event shall comply with Applicable Law.
- 1.3 Follow-up and Repayment: Within thirty (30) days of the Event, Recipient shall provide Sobi with a signed declaration that the Event has taken place and the funds provided under the Sponsorship used in full in accordance with the terms of this Agreement or inform Sobi if any funds provided remain. Recipient undertakes to repay refundable parts of the Sponsorship if the Event is cancelled, if

this Agreement is terminated pursuant to Section 3.5 or if there are any remaining funds after the Event. Such payment shall be made within thirty (30) days of the cancellation, termination or Event.

- .
- 1.4 Benefits of Sponsorship: In return for Sobi sponsoring the Meeting Recipient shall provide Sobi with the benefits specified in Schedule 2.
- 1.5 Payment:
- 1.6 The Sponsorship will be paid as specified in Schedule 1.
- 1.7 Payment Terms: All payments hereunder shall be made within thirty (30) days via bank transfer or from receipt of invoice provided that the following conditions shall have been met: invoices shall be specified as to Sobi contact person Julie Trolle. Sobi's invoice address is: Sobi, Sorgenfrivej 17, 2800 Lyngby.
- 1.8 Use of Sobi name: Recipient shall only use the name and logotypes of Sobi, in publications, presentations, programmes, other printed or orally presented materials or otherwise, after prior review and approval of Sobi.
- 1.9 Publication of Sponsorship: Recipient undertakes to declare that the Event has been sponsored by Sobi whenever any written or oral information is shared in public about the Event. If Recipient has a website, then this shall include publishing information of the Sponsorship on its website. Sobi may use the name or logo of Recipient to publish the Sponsorship on its website, as well as reporting it to all local governing bodies, as appropriate, in accordance with transparency requirements. No inducement: Recipient acknowledges that provision of the Sponsorship is in no way an inducement to recommend, prescribe, purchase, supply, sell or administer a particular medicinal product.
- 1.10 Hospitality, programme and venue of the Meeting: The Recipient represents and warrants to Sobi that
- (a) Hospitality made directly or indirectly available during the Meeting shall be kept at a reasonable level and remain secondary to the principal scientific purpose of the Meeting, be limited to the organisation and/or defrayment of the costs of travel, meals, accommodation and registration, shall not extend beyond the official duration of the Meeting and shall not include payment for or the organization of sports or leisure activities or any other form of entertainment;
- (b) The value of meals provided, drinks included, shall not exceed the limits

laid down by Applicable Law, including applicable local industry guidelines;

(c) The Meeting shall be predominantly scientific in nature and activities with a scientific purpose shall, in terms of time, take up the greater part of each day of the Meeting; and

(d) The Meeting shall take place at a suitable venue that aids the scientific purpose of the event and the place, date and duration of the Meeting and travel shall not in any case be of a nature to create any uncertainty as to its scientific nature.

(e) Where applicable, a positive e4ethics assessment has been obtained for the Event, as required under the EFPIA Code, a copy of which shall upon request be provided to Sobi.

2. DATA PRIVACY AND TRANSPARENCY

2.1 EU privacy law requires that Sobi provide Recipient and/or its representative(s) notice that Sobi and its group companies may collect, use and retain such representatives' personal data (e.g. name and contact details) provided in this contract Agreement for administration, reimbursement, and internal evaluation purposes. Sobi will process the personal data to the extent necessary to fulfil Sobi's duties under this contract Agreement and for the purpose of Sobi's legitimate interest as contractor. Sobi may share the representatives' personal data within the Sobi group and with Sobi service providers and agents for the purposes stated in this Section 3.1. Such sharing may include transfer to third countries, i.e. countries outside the EU/EESA area. When transferring the representatives' personal data to third countries, Sobi will ensure that the transfer is subject to appropriate safeguards and that the representatives' rights are protected. Typically, Sobi will enter into standard contractual clauses adopted by the eu commission with companies in third countries receiving personal data from Sobi. Sobi applies different retention periods for different categories of personal data. When processing of the representatives' personal data is no longer necessary in relation to the purpose for which it was collected Sobi will erase the personal data. The representatives have the right to access the personal data that Sobi processes concerning the representatives and to request that Sobi rectifies any inaccurate personal data and under certain circumstances request erasure and/or restriction of processing of the personal data. The representatives have the right to object to processing and to receive the processed personal data in a structured, commonly used and machine-readable format and has the right to transmit those data to another controller. The representatives also have the right to lodge a complaint to the local supervisory authority ("Datatilsynet") regarding how Sobi processes

such representatives' personal data. Recipient undertakes to share the information provided in this Section 2.1 with all representatives engaged by Recipient or on its behalf in connection with this Agreement and whose personal data will be shared with Sobi..

- 2.2 "Parties"/"Party" further acknowledges and agrees that Sobi has an annual reporting obligation to ENLI (Ethical Committee for the Pharmaceutical Industry) about the HCO/PO they have had a relationship with during the year.
- 2.3 In addition, "Parties"/"Party" acknowledges and agrees that Sobi documents all relationships required to be disclosed with ENLI and maintains the relevant records of the disclosures for a minimum of 5 years after the end of the relevant reporting period (unless a shorter period is required under applicable national data privacy or other laws or regulations). Thereafter the data will be deleted by Sobi.

3. MISCELLANEOUS

- 3.1 **Entire Agreement:** This Agreement, including its Schedules, constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior oral or written agreements of the parties with respect to such subject matter
- 3.2 **Amendments:** No provision of this Agreement may be amended, modified or otherwise changed, other than by an instrument in writing duly executed on behalf of the parties to this Agreement.
- 3.3 **Assignments:** This Agreement is personal to the parties who shall not have any right to assign it without the prior written consent of the other party, except that Sobi shall have the right to assign the Agreement to its affiliates.
- 3.4 **Independent Contractors:** In making and performing this Agreement, the parties are acting and shall act at all times as independent contractors, and nothing contained in this Agreement shall be construed or implied to create any agency, partnership or employer and employee relationship between Sobi and Recipient. At no time shall any party make commitments or incur any charges or expenses for or in the name of any other party, other than as expressly set forth herein.
- 3.5 **Survival:** Sections 1.3, 1.9, 2.6, 2.7, 2.8, 3.2 shall survive the termination or expiration of this Agreement.

3.6 Governing Law: This Agreement shall be governed and construed by the substantive laws of Denmark. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by the courts of the above said country

[Signatures to follow on the next page.]

This Agreement has been signed by each Party's duly authorized signatory(ies). This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original and all of which shall constitute together one and the same document. The Parties agree that the execution of this Agreement by electronic means using standard industry signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures, and in any proceeding arising under or relating to this Agreement, each Party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed Agreement electronically.

Swedish Orphan Biovitrum A/S

Denmark's Bleeding Association

DocuSigned by:
Mia Enochsén
E88695B007694FF...

DocuSigned by:
Karen Binger Holm
DB20472E768C480...

Name: Mia Enochsén
Title: Country Manager Denmark &
Iceland
Date:

Name: Karen Binger Holm
Title: Head of the Secretariat
Date:

:

SCHEDULE 1

SPONSORSHIP AND COSTS

Denmark's Bleeding Association has requested Sobi to support the development of new functions in the bleeding edge version 2.0.

Sobi has agreed to sponsor DKK 100.000.

SCHEDULE 2

BENEFITS OF THE SPONSORSHIP

All medical companies with the haemophilia area will / or has received a request to sponsor the Telemedicine App. The app will ensure that the patients and treaters have the possibility to report important health issues re. haemophilia and bleedings disorders.

In return we will have opportunity to meet with the Danish Bleeding Ass. and get reports from the Telemedicine app. Further the haemophgilia treaters are involved – and we also have the possibility to discuss the Telemedicine app with the treaters.

Finally Sobi will have our Sobi logo in the Patient Organization Magazine.